PTC Therapeutics, Inc.
PTCTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States. Valued at $5.78B, PTCT is a mid-cap name in its sector. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Market Cap
$5.78B
Beta
0.55
P/E (TTM)
—
P/E (Fwd)
27.72
EPS (TTM)
$-0.67
EPS (Fwd)
$2.50
ROE
—
ROA
2.5%
Cash
$2.23B
Total Debt
$3.02B
Free CF
-$286.8M
52W Change
18.6%
Annual Financials
Cash vs Debt
Where PTCT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PTCT finished 0.58% below its 150-day moving average ($72.21) and 2.19% below its 200-day moving average ($73.40). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PTCT overbought or oversold?
At the September 3, 2026 close, PTCT's RSI(14) was 49.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, PTCT has $2.23B in cash with $3.02B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$286.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROA of 2.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $698.8M (2022) to $1.73B (2025), reflecting a 148% increase over the period.
PTCT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence PTC Therapeutics, Inc.'s trajectory.